Issue Preview: J&J Ottava pivotal gastric bypass data filed with FDA · Insulet posts 34% revenue growth, raises 2026 guidance · Neptune Medical GI robot hits 100% in colonoscopy trial
Issue #20 | May 7, 2026 | The Robots Are Going Deeper
Three robotics studies dropped in the same 48-hour window. J&J published pivotal data for Ottava in gastric bypass and formally submitted to the FDA for de novo authorization. Neptune Medical’s Triton colonoscopy robot met both endpoints in a 50-patient first-in-human trial with zero adverse events. And while surgical robots fight for OR time, Insulet posted 34% revenue growth on its insulin patch pump, raised full-year guidance, and reminded everyone that the quiet device companies are still compounding. Welcome to Issue #20 of The MedTech Minute.
Johnson & Johnson announced on May 5 that its Ottava robotic surgical system met both safety and efficacy endpoints in a 30-patient pivotal study evaluating gastric bypass surgery. All procedures were completed robotically without conversion to a non-robotic approach. No adverse events were related to the device. Average weight loss at 30 days was 30 pounds. The data were presented at the American Society for Metabolic and Bariatric Surgery annual meeting in San Antonio and included in J&J’s FDA de novo submission for Ottava, which was announced in January, covering multiple upper abdominal procedures. (Source: J&J, May 5, 2026)
Ottava incorporates four robotic arms directly into a standard surgical table, eliminating the separate cart or boom structure that creates operating room footprint constraints. In the gastric bypass study, the system was installed across six hospitals with OR sizes ranging from 243 to 694 square feet, including rooms that had never been used for robotic surgery due to space limitations. J&J is targeting clearance covering gastric bypass, gastric sleeve, small bowel resection, and hiatal hernia repair; an investigational device exemption trial for inguinal hernia repair is also underway.
Why It Matters: Ottava’s table-integrated architecture directly addresses the single biggest practical barrier to robotic surgery adoption: OR square footage. A clearance in 2026 puts J&J into direct commercial competition with Intuitive Surgical’s da Vinci in every hospital that previously couldn’t accommodate a robot.
Surgical RoboticsClinical DataFDA De Novo
Why This Matters for Builders
J&J designed Ottava to solve an infrastructure problem, not a clinical one. Robotic surgery’s clinical value has been demonstrated for years. What has limited adoption is OR space, capital cost, and the learning curve attached to a proprietary cart system. Ottava answers all three: table-integrated arms remove the footprint barrier, and J&J’s existing hospital relationships compress the commercial launch cycle. For founders building capital equipment for the OR: the constraint is almost never the science. It is almost always the hospital workflow and physical infrastructure the science has to land inside.
Insulet reported Q1 2026 revenue of $761.7 million on May 6, a 33.9% increase year-over-year driven by Omnipod sales of $758.4 million. International Omnipod revenue of $242.9 million was up 59.4%, reflecting expanding reimbursement coverage in established European markets including the U.K., France, and Germany, and a faster-than-expected conversion from Omnipod Dash to the newer Omnipod 5 system. Net income of $91.1 million compared to $35.4 million in the year-ago period. CEO Ashley McEvoy raised full-year 2026 constant-currency revenue guidance to 21%–23% from the prior range of 20%–22%, driven by international growth expectations. (Source: Insulet Investor Relations, May 6, 2026)
Insulet also updated investors on the March recall of certain Omnipod 5 lots linked to a potential internal tubing tear. As of April 17, 29 serious injuries had been reported; McEvoy confirmed no additional adverse events since the April update. The recall generated approximately $12 million in Q1 expenses. The company is developing Omnipod 6 for a 2027 launch and has initiated a study for a fully closed loop system for Type 2 diabetes.
Why It Matters: A 34% revenue growth rate from a device company at Insulet’s scale is not routine. International Omnipod adoption is compounding on expanded reimbursement, not new technology, which is the most durable growth engine in MedTech: geography expansion into markets where the clinical case is already proven.
Neptune Medical announced on May 6 that its Triton robotic endoscopy system met both primary endpoints in the CARE 1 first-in-human study: zero adverse events and a 100% rate of cecal intubation across 50 colonoscopy procedures performed at a single center in Poland. The study also reported a 67.5% polyp detection rate and a 54.2% adenoma detection rate. Results were presented at Digestive Disease Week in Chicago. Triton is designed to improve navigation, precision, and control in lower GI tract procedures, including diagnostic colonoscopies, endoscopic mucosal resections, and endoscopic submucosal dissections. The system is not yet authorized for sale in the U.S. or international markets. (Source: Business Wire / Neptune Medical, May 6, 2026)
Neptune Medical raised $97 million in a 2024 Series D backed by Sonder Capital and Olympus, then spun out its Jupiter Endovascular subsidiary to sharpen its focus on GI robotics. Olympus (already Neptune’s Series D investor) announced a separate global distribution agreement with EndoRobotics for robotic ESD tools on May 4. Two distinct robot-assisted GI platforms from two different companies, both backed by Olympus, reaching clinical and commercial milestones in the same week.
Why It Matters: The colonoscopy market processes roughly 19 million procedures annually in the U.S. alone. Physician fatigue and ergonomic strain during long procedures are documented, measurable problems. A robotic system that posts 100% cecal intubation in a first-in-human study with zero device-related adverse events has cleared the foundational clinical bar. The commercialization path is long, but the clinical premise just got evidence.
RoboticsEndoscopyClinical DataGI
Market Movers
MedTech Stocks, Week of May 1–7, 2026
Ticker
Company
Price
Wk Change
ISRG
Intuitive Surgical
$451.73
▼ 1.4%
SYK
Stryker
$292.33
▼ 0.8%
JNJ
Johnson & Johnson
$224.62
▼ 1.2%
BDX
BD (Becton Dickinson)
$144.76
▲ 0.4%
ABT
Abbott
$86.30
▼ 4.5%
EW
Edwards Lifesciences
$83.20
▲ 1.3%
ZBH
Zimmer Biomet
$82.83
▼ 0.4%
MDT
Medtronic
$77.60
▼ 0.9%
GEHC
GE HealthCare
$61.74
▲ 1.0%
BSX ★
Boston Scientific
$56.00
▼ 10.3%
★ Biggest Mover: BSX fell 10.3% this week as the market absorbed Boston Scientific’s April 22 guidance cut. The company lowered full-year 2026 sales growth guidance from 10.5%–11.5% to 7%–8.5%, citing three headwinds: Watchman standalone procedure volume declining since February, unexpected PFA market share erosion to Medtronic, J&J, and Abbott, and urology growing only 2%. CEO Mike Mahoney called the guide-down “not something we are proud of.” Sorted by stock price, highest to lowest. Prices reflect approximate close, week of May 1–7, 2026. For illustrative purposes only.
Deep Dive
The GI Robot Race: Why the Colonoscopy Market Is the Next Surgical Robotics Battleground
In the same week that J&J filed its Ottava de novo submission for upper abdominal surgery and Neptune Medical posted first-in-human colonoscopy data, Olympus closed a distribution deal with EndoRobotics for robotic ESD tools. Three distinct robot-assisted GI moves in 48 hours is not a coincidence. It reflects a market dynamic that has been building for two years.
The colonoscopy volume gap. Roughly 19 million colonoscopies are performed annually in the U.S. Gastroenterologist supply is not growing at the same rate as the population requiring screening. The American Cancer Society’s updated guidance lowering the colorectal cancer screening start age to 45 expanded the eligible population by an estimated 20 million Americans. Robotics that can increase throughput and reduce physician fatigue address both a clinical and a workforce problem simultaneously, according to the American Society for Gastrointestinal Endoscopy.
The ergonomics economics. Repetitive endoscope manipulation during long procedures is a documented source of musculoskeletal injury among gastroenterologists, a workforce retention problem that robotic assist directly addresses. Neptune Medical’s Triton study noted “favorable ergonomic environment for endoscopists” as a finding, not an afterthought. Devices that protect physician health become hospital procurement priorities when specialist supply is tight.
The Olympus infrastructure play. Olympus distributes the dominant endoscopy hardware globally. Its parallel investments in Neptune Medical (Series D backer) and EndoRobotics (global distribution) put robotic tools inside existing commercial relationships with most GI labs worldwide. That is not a technology bet. It is a distribution infrastructure lock-in strategy executed before any single robotic platform has FDA authorization.
Neptune Medical’s Triton is not authorized for sale. J&J’s Ottava is awaiting FDA de novo classification. Neither is a commercial product today. But both cleared the clinical premise this week, and Olympus has already positioned itself to distribute whatever wins. The GI robotics race is earlier-stage than surgical robotics, which means the competitive positions are not yet locked. That window closes the moment one system earns authorization and signs the first multi-year hospital contracts.
The Builder’s Take
Insulet’s 34% Growth Rate Has Nothing to Do With a New Product.
Omnipod 5 launched in the U.S. in 2022. The hardware hasn’t materially changed. What is driving 34% revenue growth in Q1 2026 is expanded reimbursement coverage in Europe, geography by geography, allowing the same device to reach patients who were previously excluded by payer access. This is the most overlooked growth lever in MedTech: a cleared device with proven clinical outcomes that is simply unavailable to most of its potential market because reimbursement hasn’t followed. Insulet spent years getting European payers to cover Omnipod 5, and the compounding is now visible on the income statement. Reimbursement strategy is product strategy. If your cleared device has a 70% global addressable market that can’t access it today, you don’t need a better device. You need a better payer strategy.
⏳ That’s your 5-minute briefing. Below: extras if you want to go deeper.
Fun Fact
💡 Fun Fact — The First Robot in the OR
The first FDA-approved robotic surgical system was not Intuitive Surgical’s da Vinci. It was ROBODOC, cleared in 1992 for orthopedic bone preparation in hip replacement surgery, developed by Integrated Surgical Systems. Intuitive’s da Vinci received FDA clearance in 2000 for laparoscopic procedures and has since performed more than 12 million operations globally, according to Intuitive Surgical’s published data. J’s Ottava, if cleared in 2026, would become the first new soft-tissue surgical robot to reach the U.S. general surgery market in more than two decades.
Trivia
MedTech Trivia
Insulet’s Omnipod uses a tubeless patch pump architecture that distinguishes it from traditional insulin pumps. The Omnipod disposable Pod contains an embedded needle that self-inserts at activation. How long does the Pod stay on the body before it must be replaced, and what is the maximum insulin reservoir capacity in the Pod?
Your answer:
Think you know? 👇 Scroll to the footer for the answer.
👇 Answer at the bottom ↓
MedTech Crossword
✎ MedTech Crossword — Issue #20 Edition — Click a white cell to enter your answer
Click any white cell and type your answer. Arrows move between cells.
🎉 Puzzle complete! All words solved.
Across
1A Omnipod maker that posted 34% Q1 revenue growth (7)
3A Lower GI screening procedure tested by Neptune’s Triton robot (11)
4D J&J’s table-integrated surgical robot seeking FDA de novo (6)
Across
1A: INSULET
3A: COLONOSCOPY
5A: TRITON
7A: GASTRIC
Down
2D: ENDO
4D: OTTAVA
Quick Question
Ottava puts robot arms inside a surgical table to solve the OR space problem. Neptune Medical’s Triton puts robotics inside an endoscope. Is the next decade of surgical robotics about shrinking the hardware footprint, or about expanding the AI layer on top of existing platforms? Hit reply. I read every response.
If you’re building, hiring, or investing in MedTech, reply and tell me what you’re seeing. I read every response.
Sponsor
Sponsor This Newsletter
Interested in sponsoring The MedTech Minute?
The MedTech Minute is a focused, twice-weekly newsletter for the medical device industry. Get in front of the founders, engineers, investors, and clinicians who read it. Email us at themedtechminutenewsletter@gmail.com to discuss placement options.
This content is for informational purposes only and does not constitute financial, investment, or medical advice. Always consult qualified professionals before making decisions based on information in this newsletter.
That’s your MedTech Minute.
J&J’s robot fits in any OR. Neptune’s robot went all the way. Insulet just printed 34% growth without a new product. Prescribed reading: complete. No assembly required.
